Mycoplasma pneumoniae: re-emergence and beyond
Patrick M. Meyer Sauteur, Semjon Sidorov, Sabine Pereyre, Marie Gardette, Adrien Fischer, Noémie Wagner, Baptiste Lemaire, Alessandra Vitale, Gilbert Greub, René Brouillet, Onya Opota, Petra Zimmermann, Philipp KA Agyeman, Christoph Aebi, Michael Buettcher, Irena Mitrović, Marisa Hostettler, Valeria Gaia, Lisa Kottanattu, Marco Bongiovanni, Frank Imkamp, Adrian Egli, Christoph Berger, Ester Osuna, Elena Robinson, Benjamin Preiswerk, Adrian Schibli, Silvio D Brugger, Diego Gil Cordeiro, Anita Niederer-Loher, Günter Dollenmaier, Florence Barbey, Branislav Ivan, Peter M Keller, Ulrich Heininger, Sarah Tschudin-Sutter, Sören L Becker, Cihan Papan, Nina Bühler, Johannes Forster, Birgit Henrich, Colin R MacKenzie, Malik Aydin, Roger Dumke, Claire Brugerolles, Nathalie Bossuyt, Veerle Matheeussen, Mireille van Westreenen, Marius Vogel, Steven FL van Lelyveld, Dennis Souverein, Jayant Kalpoe, Sjoerd M Euser, Marco Goeijenbier, Dominic Snijders, Jacky Flipse, Theun de Groot, Maarten Heuvelmans, Baharak Afshar, Sendurann Nadarajah, Rebecca Thombre, Anna Lewis, Hannah Bransbury-Beare, Kay-Dee Hosten-Sandy, Kanchanamala Gunasekara, Nita Doshi, Jessica Leverton, Panoraia Kalapotharakou, Catherine Moore, Tim Jones, Jonathan Evans, Hollie Milton, Charlotte Dixon, Helen Gadegaard, Naoma William, Josie Evans, Stefanie Wilson, Rory Gunson, Pamela Saunders, Hanne-Dorthe Emborg, Karolina Gullsby, Miia Laine, Ville Peltola, Henrik Døllner, Frode Width Gran, Andreas Christensen, Alberto Rizzo, Alessandra Lombardi, Davide Mileto, Daniele Dona, Giulia Brigadoi, Sara Rossin, Silvia Bressan, Claudia Del Vecchio, Elisa Franchin, Marilena La Sorda, Danilo Buonsenso, Antonio Mastroianni, Sonia Greco, Fernanda MP Rodrigues
Abstract
The re-emergence of Mycoplasma pneumoniae in late 2023 placed a considerable burden on health-care systems and raised concerns regarding the severity of pneumonia outbreaks.1 The European Society of Clinical Microbiology and Infectious Diseases Study Group for Mycoplasma and Chlamydia Infections (ESGMAC) Mycoplasma pneumoniae surveillance (MAPS) study2 was able to attribute these outbreaks to M pneumoniae and found no statistically significant global increase in the proportion of severe outcomes compared with that of pre-pandemic epidemics.